Skip to main content
Top
Published in: Current Psychiatry Reports 10/2013

01-10-2013 | Complex Medical-Psychiatric Issues (MB Riba, Section Editor)

Inflammation, Heart Disease, and Depression

Author: Angelos Halaris

Published in: Current Psychiatry Reports | Issue 10/2013

Login to get access

Abstract

Morbidity and mortality of cardiovascular disease is exceedingly high worldwide. Depressive illness afflicts a significant portion of the population worldwide. Epidemiological studies have confirmed the high co-morbidity between these two entities and the co-morbidity is bidirectional. Systems that contribute to this co-morbidity include the central and autonomic nervous systems, the neuroendocrine, immune, vascular and hematologic systems. Specific pathophysiologic factors include imbalance between the sympathetic and the parasympathetic systems, sympathoadrenal activation, hypothalamic-pituitary-adrenal axis activation, immune system dysregulation with release of pro-inflammatory cytokines and chemokines, platelet activation and hypercoaguability. Inflammation occurs in cardiac and cardiovascular pathology independent of the presence or absence of depression and in depression. Inflammation is closely associated with endothelial dysfunction which is a preamble to atherosclerosis and atherothrombosis. A likely common instigator underlying this co-morbidity is mental stress leading to sustained sympathetic overdrive and diminished vagal tone. Diminished vagal tone contributes to a pro-inflammatory status which affects neurotransmitter regulation, specifically serotonergic transmission. Stress hormones and certain pro-inflammatory substances released by macrophages and microglia upregulate the rate-limiting enzymes in the metabolic pathway of tryptophan. This results in a shunt in tryprophan metabolism away from serotonin formation and down the kynurenine pathway with resulting formation of neurotoxic metabolites.
Literature
1.
go back to reference Dahlof B. Cardiovascular disease risk factors: epidemiology and risk assessment. Am J Cardiol. 2010;105(1 Suppl):3A–9A.PubMedCrossRef Dahlof B. Cardiovascular disease risk factors: epidemiology and risk assessment. Am J Cardiol. 2010;105(1 Suppl):3A–9A.PubMedCrossRef
2.
go back to reference Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction. Circulation. 2010;121(4):586–613.PubMedCrossRef Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction. Circulation. 2010;121(4):586–613.PubMedCrossRef
3.
go back to reference Waldman SA, Terzic A. Cardiovascular health: The global challenge. Clin Pharmacol Therap. 2011;90(4):483–5.CrossRef Waldman SA, Terzic A. Cardiovascular health: The global challenge. Clin Pharmacol Therap. 2011;90(4):483–5.CrossRef
4.
5.
go back to reference Kovasic JC, Fuster V. From treating complex coronary disease to promoting cardiovascular health: Therapeutic transitions and challenges 2010-2020. Clin Pharmacol Ther. 2011;90(4):509–18.CrossRef Kovasic JC, Fuster V. From treating complex coronary disease to promoting cardiovascular health: Therapeutic transitions and challenges 2010-2020. Clin Pharmacol Ther. 2011;90(4):509–18.CrossRef
6.
go back to reference Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences. Eur Heart J. 2004;25:1197–207.PubMedCrossRef Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences. Eur Heart J. 2004;25:1197–207.PubMedCrossRef
7.
go back to reference American Heart Association. Heart Disease and Stroke Statistics – 2004 update. Dallas, TX: American Heart Association. 2004. American Heart Association. Heart Disease and Stroke Statistics – 2004 update. Dallas, TX: American Heart Association. 2004.
8.
go back to reference Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349(9063):1436–42.PubMedCrossRef Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349(9063):1436–42.PubMedCrossRef
9.
go back to reference Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization world Mental Health surveys. JAMA. 2004;291:2581–90.PubMedCrossRef Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization world Mental Health surveys. JAMA. 2004;291:2581–90.PubMedCrossRef
10.
go back to reference Centers for Disease Control and Prevention (CDC). Current depression among adults – United states, 2006 and 2008. Morb Mortal Wkly Rep. 2010;59:1229–35. Centers for Disease Control and Prevention (CDC). Current depression among adults – United states, 2006 and 2008. Morb Mortal Wkly Rep. 2010;59:1229–35.
11.
go back to reference •• Lepin JP, Briley M. The increasing burden of depression. Neuropsych Dis Treat. 2011;7 Suppl 1:3–7. This article provides a brief overview of how depression affects quality of life and of the increasing burden of depression. •• Lepin JP, Briley M. The increasing burden of depression. Neuropsych Dis Treat. 2011;7 Suppl 1:3–7. This article provides a brief overview of how depression affects quality of life and of the increasing burden of depression.
12.
go back to reference Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation. 1999;99:2192–217.PubMedCrossRef Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation. 1999;99:2192–217.PubMedCrossRef
13.
go back to reference Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med. 2004;66:802–13.PubMedCrossRef Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med. 2004;66:802–13.PubMedCrossRef
14.
go back to reference Gump BB, Matthews KA, Eberly LE, Chang YF, MRFIT Research Group. Depressive symptoms and mortality in men: results from Multiple Risk Factor Intervention Trial. Stroke. 2005;36:98–102.PubMedCrossRef Gump BB, Matthews KA, Eberly LE, Chang YF, MRFIT Research Group. Depressive symptoms and mortality in men: results from Multiple Risk Factor Intervention Trial. Stroke. 2005;36:98–102.PubMedCrossRef
15.
go back to reference Halaris A. Co-morbidity between depression and cardiovascular disease. Int Angiol. 2009;28(2):92–9.PubMed Halaris A. Co-morbidity between depression and cardiovascular disease. Int Angiol. 2009;28(2):92–9.PubMed
16.
go back to reference • Saleptsis VG, Lambropoulos N, Halaris A, Angelopoulos NV, Giannoukas AD. Depression and atherosclerosis. Int Angiol. 2011;30(2):97–104. This is the most recent review of this topic.PubMed • Saleptsis VG, Lambropoulos N, Halaris A, Angelopoulos NV, Giannoukas AD. Depression and atherosclerosis. Int Angiol. 2011;30(2):97–104. This is the most recent review of this topic.PubMed
17.
go back to reference Fielding R. Depression and acute myocardial infarction: A review and reinterpretation. Soc Sci Med. 1991;32:1017–27.PubMedCrossRef Fielding R. Depression and acute myocardial infarction: A review and reinterpretation. Soc Sci Med. 1991;32:1017–27.PubMedCrossRef
18.
go back to reference Schleifer SJ, Macari-Hinson MM, Coyle DA. The nature and course of depression following myocardial infarction. Arch Intern Med. 1989;149:1785–9.PubMedCrossRef Schleifer SJ, Macari-Hinson MM, Coyle DA. The nature and course of depression following myocardial infarction. Arch Intern Med. 1989;149:1785–9.PubMedCrossRef
19.
go back to reference Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact of 6-month survival. JAMA. 1993;270:1819–25.PubMedCrossRef Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact of 6-month survival. JAMA. 1993;270:1819–25.PubMedCrossRef
20.
go back to reference Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infraction. Circulation. 1995;91:999–1005.PubMedCrossRef Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infraction. Circulation. 1995;91:999–1005.PubMedCrossRef
21.
go back to reference Lesperance F, Frasure-Smith N, Jueau M, Theroux P. Depression and 1-year prognosis in unstable angina. Arch Intern Med. 2000;160:1354–60.PubMedCrossRef Lesperance F, Frasure-Smith N, Jueau M, Theroux P. Depression and 1-year prognosis in unstable angina. Arch Intern Med. 2000;160:1354–60.PubMedCrossRef
22.
go back to reference Ahern DK, Gorkin L, Anderson JL, Tierney C, Hallstrom A, Ewart C, et al. Biobehavioral variables and mortality or cardiac arrest in the Cardiac Arrhythmia Pilot Study (CAPS). Am J Cardiol. 1990;66:59–62.PubMedCrossRef Ahern DK, Gorkin L, Anderson JL, Tierney C, Hallstrom A, Ewart C, et al. Biobehavioral variables and mortality or cardiac arrest in the Cardiac Arrhythmia Pilot Study (CAPS). Am J Cardiol. 1990;66:59–62.PubMedCrossRef
23.
go back to reference Bush DE, Ziegelstein RC, Tayback M, Richter D, Stevens S, Zahalsky H, et al. Even minimal symptoms of depression increase mortality risk after acute myocardial infection. Am J Cardiol. 2001;88:337–41.PubMedCrossRef Bush DE, Ziegelstein RC, Tayback M, Richter D, Stevens S, Zahalsky H, et al. Even minimal symptoms of depression increase mortality risk after acute myocardial infection. Am J Cardiol. 2001;88:337–41.PubMedCrossRef
24.
go back to reference Ford DE, Mead LA, Chang PP. Depression is a risk factor for coronary artery disease in men: the precursors study. Arch Intern Med. 1998;158(13):1422–26.PubMedCrossRef Ford DE, Mead LA, Chang PP. Depression is a risk factor for coronary artery disease in men: the precursors study. Arch Intern Med. 1998;158(13):1422–26.PubMedCrossRef
25.
go back to reference Ariyo AA, Haan M, Tangen CM, Ruteledge JC, Cushman M, Dobs A. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group Circulation. 2000;102:1773–79. Ariyo AA, Haan M, Tangen CM, Ruteledge JC, Cushman M, Dobs A. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group Circulation. 2000;102:1773–79.
26.
go back to reference Penninx BW, Beekman AT, Honig A, Deeg DJ, Schoevers RA, van Eijk JT. Depression and cardiac mortality: Results from a community-based longitudinal study. Arch Gen Psychiatry. 2001;58:221–7.PubMedCrossRef Penninx BW, Beekman AT, Honig A, Deeg DJ, Schoevers RA, van Eijk JT. Depression and cardiac mortality: Results from a community-based longitudinal study. Arch Gen Psychiatry. 2001;58:221–7.PubMedCrossRef
27.
go back to reference Jiang W, Alexander J, Christopher E, Kuchibhatia M, Gaulden LH, Cuffe MS. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001;161:1849–56.PubMedCrossRef Jiang W, Alexander J, Christopher E, Kuchibhatia M, Gaulden LH, Cuffe MS. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001;161:1849–56.PubMedCrossRef
28.
go back to reference Lesperance J, Frasure-Smith N, Talajic M, Bourassa M. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms in myocardial infarction. Circulation. 2002;105:1049–53.PubMedCrossRef Lesperance J, Frasure-Smith N, Talajic M, Bourassa M. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms in myocardial infarction. Circulation. 2002;105:1049–53.PubMedCrossRef
29.
go back to reference Junger J, Schellberg D, Muller-Tasch T. Depression increasingly predicts mortality in the course of congestive heart failure. Eur J Heart Fail. 2005;7:261–7.PubMedCrossRef Junger J, Schellberg D, Muller-Tasch T. Depression increasingly predicts mortality in the course of congestive heart failure. Eur J Heart Fail. 2005;7:261–7.PubMedCrossRef
30.
go back to reference Sherwood A, Blumenthal JA, Trivedi R, et al. Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med. 2007;167:367–73.PubMedCrossRef Sherwood A, Blumenthal JA, Trivedi R, et al. Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med. 2007;167:367–73.PubMedCrossRef
31.
go back to reference Eaton WW, Fogel J, Armenian HK. The consequences of psychopathology in the Baltimore Epidemiologic Catchment Area Follow-up. Medical and Psychiatric Co-morbidity over the Lifespan. Washington: American Psychiatric. 2006; pp 21–38. Eaton WW, Fogel J, Armenian HK. The consequences of psychopathology in the Baltimore Epidemiologic Catchment Area Follow-up. Medical and Psychiatric Co-morbidity over the Lifespan. Washington: American Psychiatric. 2006; pp 21–38.
32.
go back to reference Wulsin LR, Evans JC, Vasan RS, Murabito JM, Kelly-Hayes M, Benjamin E. Depressive symptoms, coronary heart disease, and overall mortality in the Framingham Heart Study. Psychosom Med. 2005;67:697–702.PubMedCrossRef Wulsin LR, Evans JC, Vasan RS, Murabito JM, Kelly-Hayes M, Benjamin E. Depressive symptoms, coronary heart disease, and overall mortality in the Framingham Heart Study. Psychosom Med. 2005;67:697–702.PubMedCrossRef
33.
go back to reference Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998;55:580–92.PubMedCrossRef Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998;55:580–92.PubMedCrossRef
34.
go back to reference O’Connor CM, Gurbel PA, Serebruany VL. Depression in ischemic heart disease. Am Heart J. 2000;140:63–9.PubMedCrossRef O’Connor CM, Gurbel PA, Serebruany VL. Depression in ischemic heart disease. Am Heart J. 2000;140:63–9.PubMedCrossRef
35.
go back to reference Carney RM, Jaffe AS. Treatment of depression following acute myocardial infarction. JAMA. 2002;288:750–1.PubMedCrossRef Carney RM, Jaffe AS. Treatment of depression following acute myocardial infarction. JAMA. 2002;288:750–1.PubMedCrossRef
36.
go back to reference Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J. 2006;27:2763–74.PubMedCrossRef Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J. 2006;27:2763–74.PubMedCrossRef
37.
go back to reference Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol. 2007;74:224–42.PubMedCrossRef Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol. 2007;74:224–42.PubMedCrossRef
38.
go back to reference Otte C, Neylan TC, Pipkin SS, Browner WS, Whooley MA. Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul Study. Am J Psychiatry. 2005;162(11):2139–45.PubMedCrossRef Otte C, Neylan TC, Pipkin SS, Browner WS, Whooley MA. Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul Study. Am J Psychiatry. 2005;162(11):2139–45.PubMedCrossRef
39.
go back to reference Licht CMM, de Geus EJC, Zitman FG, Hoogendijk WJG, van Dyck R, Penninx BWJH. Association between major depressive disorder and heart rate variability in the Netherlands study of depression and anxiety (NESDA). Arch Gen Psychiat. 2008;65912:1358–67.CrossRef Licht CMM, de Geus EJC, Zitman FG, Hoogendijk WJG, van Dyck R, Penninx BWJH. Association between major depressive disorder and heart rate variability in the Netherlands study of depression and anxiety (NESDA). Arch Gen Psychiat. 2008;65912:1358–67.CrossRef
40.
go back to reference Porges SW. The polyvagal theory: phylogenetic substrates of a social nervous system. Int J Psychophysiol. 2001;42(2):123–46.PubMedCrossRef Porges SW. The polyvagal theory: phylogenetic substrates of a social nervous system. Int J Psychophysiol. 2001;42(2):123–46.PubMedCrossRef
41.
go back to reference Porges SW. Cardiac vagal tone; a physiological index of stress. Neurosci Biobehav Rev. 1995;19(2):225–33.PubMedCrossRef Porges SW. Cardiac vagal tone; a physiological index of stress. Neurosci Biobehav Rev. 1995;19(2):225–33.PubMedCrossRef
42.
go back to reference Porges SW. Emotion: an evolutionary by-product of the neural regulation of the autonomic nervous system. Ann NY Acad Sci. 1997;807:62–77.PubMedCrossRef Porges SW. Emotion: an evolutionary by-product of the neural regulation of the autonomic nervous system. Ann NY Acad Sci. 1997;807:62–77.PubMedCrossRef
44.
go back to reference Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis. 2003;169:203–14.PubMedCrossRef Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis. 2003;169:203–14.PubMedCrossRef
45.
go back to reference Frasure-Smith N, Lespérance F, Irwin MR, Sauvé C, Lespérance J, Théroux P. Depression, C-reactive protein and two-year major adverse cardiac events in men after acute coronary syndromes. Biol Psychiatry. 2007;62(4):302–8.PubMedCrossRef Frasure-Smith N, Lespérance F, Irwin MR, Sauvé C, Lespérance J, Théroux P. Depression, C-reactive protein and two-year major adverse cardiac events in men after acute coronary syndromes. Biol Psychiatry. 2007;62(4):302–8.PubMedCrossRef
46.
go back to reference Hansson G. Inflammation, atherosclerosis, and coronary artery disease. New Engl J Med. 2005;352(16):1685–95.PubMedCrossRef Hansson G. Inflammation, atherosclerosis, and coronary artery disease. New Engl J Med. 2005;352(16):1685–95.PubMedCrossRef
47.
go back to reference Seta Y, Shan K, Bozkurt B, et al. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail. 1996;2:243–9.PubMedCrossRef Seta Y, Shan K, Bozkurt B, et al. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail. 1996;2:243–9.PubMedCrossRef
48.
go back to reference Petersen JW, Felker M. Inflammatory biomarkers in heart failure. Congest Heart Fail. 2006;12(6):324–8.PubMedCrossRef Petersen JW, Felker M. Inflammatory biomarkers in heart failure. Congest Heart Fail. 2006;12(6):324–8.PubMedCrossRef
49.
go back to reference Maes M, Bosmans E, Suy E, Vandervorst C, DeJonckheere C, Raus J. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiat Scand. 1991;84:379–86.PubMedCrossRef Maes M, Bosmans E, Suy E, Vandervorst C, DeJonckheere C, Raus J. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiat Scand. 1991;84:379–86.PubMedCrossRef
50.
go back to reference Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19:11–38.PubMedCrossRef Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19:11–38.PubMedCrossRef
51.
go back to reference Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol. 2002;5:375–88.PubMedCrossRef Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol. 2002;5:375–88.PubMedCrossRef
52.
go back to reference Lee KM, Kim YK. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int Immunopharmacol. 2006;6:1298–304.PubMedCrossRef Lee KM, Kim YK. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int Immunopharmacol. 2006;6:1298–304.PubMedCrossRef
53.
54.
55.
go back to reference Robbins M, Topol EJ. Inflammation in acute coronary syndromes. Cleve Clin J Med. 2002;69 Suppl 2:SII130–42.PubMedCrossRef Robbins M, Topol EJ. Inflammation in acute coronary syndromes. Cleve Clin J Med. 2002;69 Suppl 2:SII130–42.PubMedCrossRef
56.
go back to reference Maes M, Bosmans E, Meltzer HY, Scharpe S, Suy E. Interleukin-1 beta: A putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry. 1993;150:1189–93.PubMed Maes M, Bosmans E, Meltzer HY, Scharpe S, Suy E. Interleukin-1 beta: A putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry. 1993;150:1189–93.PubMed
57.
go back to reference Maes M, der Planken V, Van Gastel A, Desnyder R. Blood coagulation and platelet aggression in major depression. J Affect Disord. 1996;40:35–40.PubMedCrossRef Maes M, der Planken V, Van Gastel A, Desnyder R. Blood coagulation and platelet aggression in major depression. J Affect Disord. 1996;40:35–40.PubMedCrossRef
58.
go back to reference Kop WJ, Gottdiener JS, Tangen CM, Fried LP, McBurnie MA, Walston J. Inflammation and coagulation factors on persons > 65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am J Cardiol. 2002;89:419–24.PubMedCrossRef Kop WJ, Gottdiener JS, Tangen CM, Fried LP, McBurnie MA, Walston J. Inflammation and coagulation factors on persons > 65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am J Cardiol. 2002;89:419–24.PubMedCrossRef
59.
go back to reference Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry. 2001;158:1252–7.PubMedCrossRef Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry. 2001;158:1252–7.PubMedCrossRef
60.
go back to reference Connor TJ, Leonard BE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 1998;62:583–606.PubMedCrossRef Connor TJ, Leonard BE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 1998;62:583–606.PubMedCrossRef
61.
go back to reference Leonard BE. Brain cytokines and the psychopathology of depression. In: Leonard BE, editor. Antidepressants. Basel: Birkhauser Verlag; 2001. p. 109–20.CrossRef Leonard BE. Brain cytokines and the psychopathology of depression. In: Leonard BE, editor. Antidepressants. Basel: Birkhauser Verlag; 2001. p. 109–20.CrossRef
62.
go back to reference Castanon N, Leonard BE, Neveu PJ, Yirmiya R. Effects of antidepressants on cytokine production and actions. Brain Behav Immun. 2002;16:569–74.PubMedCrossRef Castanon N, Leonard BE, Neveu PJ, Yirmiya R. Effects of antidepressants on cytokine production and actions. Brain Behav Immun. 2002;16:569–74.PubMedCrossRef
63.
go back to reference Leonard BE, Myint A. Inflammation and depression: Is there a causal connection with dementia? Neutox Res. 2006;10:149–60. Leonard BE, Myint A. Inflammation and depression: Is there a causal connection with dementia? Neutox Res. 2006;10:149–60.
64.
go back to reference von Känel R, Hepp U, Kraemer B, Traber R, Keel M, Mica L, et al. Evidence for low-grade systemic proinflammatory activity in patients with posttraumatic stress disorder. J Psychiatr Res. 2006;41:744–52.CrossRef von Känel R, Hepp U, Kraemer B, Traber R, Keel M, Mica L, et al. Evidence for low-grade systemic proinflammatory activity in patients with posttraumatic stress disorder. J Psychiatr Res. 2006;41:744–52.CrossRef
65.
go back to reference Empana JP, Sykes DH, Luc G, Juhan-Vague I, Arveiler D, Ferrieres J, et al. Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 2005;111:2299–305.PubMedCrossRef Empana JP, Sykes DH, Luc G, Juhan-Vague I, Arveiler D, Ferrieres J, et al. Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 2005;111:2299–305.PubMedCrossRef
66.
go back to reference Anda R, Williamson D, Jones D, Macera C, Eaker E, Glassman A, et al. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology. 1993;4:285–94.PubMedCrossRef Anda R, Williamson D, Jones D, Macera C, Eaker E, Glassman A, et al. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology. 1993;4:285–94.PubMedCrossRef
67.
go back to reference Kamphuis MH, Kalmijn S, Tijhuis MA, Geerlings MI, Giampaoli S, Nissinen A, et al. Depressive symptoms as risk factor of cardiovascular mortality in older European men: the Finland, Italy and Netherlands Elderly (FINE) study. Eur J Cardiovasc Prev Rehabil. 2006;13:199–206.PubMedCrossRef Kamphuis MH, Kalmijn S, Tijhuis MA, Geerlings MI, Giampaoli S, Nissinen A, et al. Depressive symptoms as risk factor of cardiovascular mortality in older European men: the Finland, Italy and Netherlands Elderly (FINE) study. Eur J Cardiovasc Prev Rehabil. 2006;13:199–206.PubMedCrossRef
68.
go back to reference Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation. 1996;94:3123–9.PubMedCrossRef Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation. 1996;94:3123–9.PubMedCrossRef
69.
go back to reference Di Iorio A, Ferrucci L, Sparvieri E, Cherubini A, Volpato S, Corsi A, et al. Abate, Paganelli R. Serum IL-1beta levels in health and disease: a population-based study. 'The InCHIANTI study'. Cytokine. 2003;22:198–205.PubMedCrossRef Di Iorio A, Ferrucci L, Sparvieri E, Cherubini A, Volpato S, Corsi A, et al. Abate, Paganelli R. Serum IL-1beta levels in health and disease: a population-based study. 'The InCHIANTI study'. Cytokine. 2003;22:198–205.PubMedCrossRef
70.
go back to reference Biasucci LM. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation. 2004;110:e560–7.PubMedCrossRef Biasucci LM. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation. 2004;110:e560–7.PubMedCrossRef
71.
72.
go back to reference Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci. 2001;933:222–34.PubMedCrossRef Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci. 2001;933:222–34.PubMedCrossRef
73.
go back to reference Vollmer-Conna U, Fazou C, Cameron B, Li H, Brennan C, Luck L, et al. Production of pro-inflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychol Med. 2004;34:1289–97.PubMedCrossRef Vollmer-Conna U, Fazou C, Cameron B, Li H, Brennan C, Luck L, et al. Production of pro-inflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychol Med. 2004;34:1289–97.PubMedCrossRef
75.
go back to reference Ur E, White PD, Grossman A. Hypothesis: cytokines may be activated to cause depressive illness and chronic fatigue syndrome. Eur Arch Psychiatry Clin Neurosci. 1992;241(5):317–22.PubMedCrossRef Ur E, White PD, Grossman A. Hypothesis: cytokines may be activated to cause depressive illness and chronic fatigue syndrome. Eur Arch Psychiatry Clin Neurosci. 1992;241(5):317–22.PubMedCrossRef
76.
go back to reference Lett HS, Blumenthal JA, Babyak MA, Sherwood A, Strauman T, Robins C, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med. 2004;66:305–15.PubMedCrossRef Lett HS, Blumenthal JA, Babyak MA, Sherwood A, Strauman T, Robins C, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med. 2004;66:305–15.PubMedCrossRef
77.
go back to reference Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacol. 2000;22:370–9.CrossRef Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacol. 2000;22:370–9.CrossRef
78.
go back to reference Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol. 2001;21:199–206.PubMedCrossRef Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol. 2001;21:199–206.PubMedCrossRef
79.
go back to reference Kubera M, Kenis G, Bosmans E, Kajta M, Basta-Kaim A, Scharpe S, et al. Stimulatory effect of antidepressants on the production of IL-6. Int Immunopharmacol. 2004;4:185–92.PubMedCrossRef Kubera M, Kenis G, Bosmans E, Kajta M, Basta-Kaim A, Scharpe S, et al. Stimulatory effect of antidepressants on the production of IL-6. Int Immunopharmacol. 2004;4:185–92.PubMedCrossRef
80.
go back to reference Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol. 2002;5:401–12.PubMedCrossRef Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol. 2002;5:401–12.PubMedCrossRef
81.
go back to reference Himmerich H, Binder EB, Künzel HE, Schuld A, Lucae S, Uhr M, et al. Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biol Psychiatry. 2006;60:882–8.PubMedCrossRef Himmerich H, Binder EB, Künzel HE, Schuld A, Lucae S, Uhr M, et al. Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biol Psychiatry. 2006;60:882–8.PubMedCrossRef
82.
go back to reference Mayer B, Holmer SR, Hengstenberg C, Lieb W, Pfeifer M, Schunkert H. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. Int J Cardiol. 2005;103:182–6.PubMedCrossRef Mayer B, Holmer SR, Hengstenberg C, Lieb W, Pfeifer M, Schunkert H. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. Int J Cardiol. 2005;103:182–6.PubMedCrossRef
83.
go back to reference Janssen DG, Caniato RN, Verster JC, Baune BT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Human Psychopharmacol. 2010;25:201–15.CrossRef Janssen DG, Caniato RN, Verster JC, Baune BT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Human Psychopharmacol. 2010;25:201–15.CrossRef
84.
go back to reference Müller N, Schwarz MJ, Dehning S, Douhe A. Cerovecki Aet al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11:680–4.PubMedCrossRef Müller N, Schwarz MJ, Dehning S, Douhe A. Cerovecki Aet al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11:680–4.PubMedCrossRef
85.
go back to reference Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JMC. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci. 2000;98:531–5.PubMedCrossRef Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JMC. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci. 2000;98:531–5.PubMedCrossRef
86.
go back to reference Piletz JE, Halaris A, Iqbal O, et al. Pro-inflammatory biomarkers in depression: treatment with venlafaxine. World J Biol Psychiatry. 2009;10:313–23.PubMedCrossRef Piletz JE, Halaris A, Iqbal O, et al. Pro-inflammatory biomarkers in depression: treatment with venlafaxine. World J Biol Psychiatry. 2009;10:313–23.PubMedCrossRef
87.
go back to reference Dinan TG. Inflammatory markers in depression. Curr Opin Psychiatry. 2008;22:32–6.CrossRef Dinan TG. Inflammatory markers in depression. Curr Opin Psychiatry. 2008;22:32–6.CrossRef
88.
go back to reference Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat rev Neurosci. 2008;9(1):46–56.PubMedCrossRef Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat rev Neurosci. 2008;9(1):46–56.PubMedCrossRef
89.
go back to reference Leonard BE. The concept of depression as a dysfunction of the immune system. Curr Immunol Rev. 2010;6(3):205–12.PubMedCrossRef Leonard BE. The concept of depression as a dysfunction of the immune system. Curr Immunol Rev. 2010;6(3):205–12.PubMedCrossRef
90.
91.
go back to reference Tucci M, Quatraro C, Frassanito MA, Silvestris F. Deregulated expression of monocyte chemoattractant protein-1 (MCP-1) in arterial hypertension: role in endothelial inflammation and atheromasia. J Hypertens. 2006;24:1307–18.PubMedCrossRef Tucci M, Quatraro C, Frassanito MA, Silvestris F. Deregulated expression of monocyte chemoattractant protein-1 (MCP-1) in arterial hypertension: role in endothelial inflammation and atheromasia. J Hypertens. 2006;24:1307–18.PubMedCrossRef
92.
go back to reference Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation. 2003;108:2054–9.PubMedCrossRef Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation. 2003;108:2054–9.PubMedCrossRef
93.
go back to reference Rybakowski JK, Wykretowicz A, Heymann-Szlachcinska A, Wysocki H. Impairment of endothelial function in unipolar and bipolar depression. Biol Psychiatry. 2006;60:889–91.PubMedCrossRef Rybakowski JK, Wykretowicz A, Heymann-Szlachcinska A, Wysocki H. Impairment of endothelial function in unipolar and bipolar depression. Biol Psychiatry. 2006;60:889–91.PubMedCrossRef
94.
go back to reference Broadley AJ, Korszun A, Jones CJ, Frenneaux MP. Arterial endothelial function is impaired in treated depression. Heart. 2002;88:521–23.PubMedCrossRef Broadley AJ, Korszun A, Jones CJ, Frenneaux MP. Arterial endothelial function is impaired in treated depression. Heart. 2002;88:521–23.PubMedCrossRef
95.
go back to reference Mendelson SD. The current status of the platelet 5-HT (2A) receptor in depression. J Affect Disord. 2000;57:13–24.PubMedCrossRef Mendelson SD. The current status of the platelet 5-HT (2A) receptor in depression. J Affect Disord. 2000;57:13–24.PubMedCrossRef
96.
go back to reference Hrdina PD, Bakish D, Chudzik J, Ravindran A, Lapierre YD. Serotonergic markers in platelets of patients with major depression: upregulation of 5-HT2 receptors. J Psychiat Neurosci. 1995;20:11–9. Hrdina PD, Bakish D, Chudzik J, Ravindran A, Lapierre YD. Serotonergic markers in platelets of patients with major depression: upregulation of 5-HT2 receptors. J Psychiat Neurosci. 1995;20:11–9.
97.
go back to reference Neuger J, El Khoury A, Kjellman BF, Wahlund B, Aberg-Wistedt A, Stain-Malgren R. Platelet serotonin functions in untreated major depression. Psychiatry Res. 1999;85:189–98.PubMedCrossRef Neuger J, El Khoury A, Kjellman BF, Wahlund B, Aberg-Wistedt A, Stain-Malgren R. Platelet serotonin functions in untreated major depression. Psychiatry Res. 1999;85:189–98.PubMedCrossRef
98.
go back to reference Shimbo D, Child J, Davidson K, Geer E, Osende JI, Reddy S, et al. Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes. Am J Cardiol. 2002;89:331–3.PubMedCrossRef Shimbo D, Child J, Davidson K, Geer E, Osende JI, Reddy S, et al. Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes. Am J Cardiol. 2002;89:331–3.PubMedCrossRef
99.
go back to reference Whyte EM, Pollock BG, Wagner WR, Mulsant BH, Ferrell RE, Mazumdar S, et al. Influence of serotonin-transporter-linked promoter region polymorphism on platelet activation in geriatric depression. Am J Psychiatry. 2001;158:2074–76.PubMedCrossRef Whyte EM, Pollock BG, Wagner WR, Mulsant BH, Ferrell RE, Mazumdar S, et al. Influence of serotonin-transporter-linked promoter region polymorphism on platelet activation in geriatric depression. Am J Psychiatry. 2001;158:2074–76.PubMedCrossRef
100.
go back to reference Palazzolo DL, Quadri SK. Interleukin-1 inhibits serotonin release from the hypothalamus in vitro. Life Sci. 1992;51:1797–802.PubMedCrossRef Palazzolo DL, Quadri SK. Interleukin-1 inhibits serotonin release from the hypothalamus in vitro. Life Sci. 1992;51:1797–802.PubMedCrossRef
101.
go back to reference Zhu CB, Blakely RD, Hewlett WA. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacol. 2006;31:2121–31. Zhu CB, Blakely RD, Hewlett WA. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacol. 2006;31:2121–31.
102.
go back to reference •• Christmas DM, Potokar JP, Davies SJC. A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase. Neurpsych Dis Treat. 2011;7:431–9. •• Christmas DM, Potokar JP, Davies SJC. A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase. Neurpsych Dis Treat. 2011;7:431–9.
103.
go back to reference Myint AM, Kim YK, Verkerk R, Scharpé S, Steinbusch HWM, Leonard BE. Kynurenine pathway in Major Depression: Evidence of impaired neuroprotection. J Affect Disord. 2007;89(1):143–51.CrossRef Myint AM, Kim YK, Verkerk R, Scharpé S, Steinbusch HWM, Leonard BE. Kynurenine pathway in Major Depression: Evidence of impaired neuroprotection. J Affect Disord. 2007;89(1):143–51.CrossRef
104.
go back to reference Myint AH, Kim YK. Cytokine-serotonin interaction through IDO; a neurodegeneration hypothesis of depression. Med Hypotheses. 2003;61(5–6):519–25.PubMedCrossRef Myint AH, Kim YK. Cytokine-serotonin interaction through IDO; a neurodegeneration hypothesis of depression. Med Hypotheses. 2003;61(5–6):519–25.PubMedCrossRef
105.
go back to reference Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 2006;1073–1074:25–37.PubMedCrossRef Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 2006;1073–1074:25–37.PubMedCrossRef
106.
go back to reference Myint AM, Kim YK, Verkerk R, Park SH, Scharpe S, Steinbusch HW, et al. Tryptophan breakdown pathway in bipolar mania. J Affect Disord. 2007;102(1–3):65–72.PubMedCrossRef Myint AM, Kim YK, Verkerk R, Park SH, Scharpe S, Steinbusch HW, et al. Tryptophan breakdown pathway in bipolar mania. J Affect Disord. 2007;102(1–3):65–72.PubMedCrossRef
Metadata
Title
Inflammation, Heart Disease, and Depression
Author
Angelos Halaris
Publication date
01-10-2013
Publisher
Springer US
Published in
Current Psychiatry Reports / Issue 10/2013
Print ISSN: 1523-3812
Electronic ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-013-0400-5

Other articles of this Issue 10/2013

Current Psychiatry Reports 10/2013 Go to the issue

Complex Medical-Psychiatric Issues (MB Riba, Section Editor)

The Brain in Overdrive: A New Look at Borderline and Related Disorders

Eating Disorders (AS Kaplan, Section Editor)

Psychiatric Aspects of Bariatric Surgery

Complex Medical-Psychiatric Issues (MB Riba, Section Editor)

Dissociative Disorders in Medical Settings

Complex Medical-Psychiatric Issues (MB Riba, Section Editor)

Psychopharmacology for Medically Ill Adolescents